Featured News

CFB Client Secures $3M Public and Private Investment

Nov 14 2017
NEW YORK, NY

Codagenix, Inc., a clinical stage, venture and p

Learn More

Traverse Biosciences Accepted into NIH Commercialization Accelerator Program (CAP)Sep 29 2017

Traverse Biosciences, lead by CFB BioEn

Learn More

CFB BEIR Receives $1.9M SBIR Fast-TrackSep 20 2017

Avanti Biosciences, Inc. a preclinical-

Learn More
  • CFB Client Secures $3M Public and Private InvestmentNovember 14, 2017

    Codagenix, Inc., has secured an additional $3M in funding in support of its live-attenuated Respiratory Syncytial Virus (RSV) vaccine candidate that was developed in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH.

    Learn More
  • Traverse Biosciences Accepted into NIH Commercialization Accelerator Program (CAP)September 29, 2017

    CFB BEIR-led Traverse Biosciences will enter the exclusive 9-month program which enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.

    Learn More
  • CFB BEIR Receives $1.9M SBIR Fast-TrackSeptember 20, 2017

    Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by CFB BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule Alzheimer’s disease (AD) over the next 3 years.

    Learn More

Upcoming Events

  • INTENSIVE SBIR/STTR WORKSHOP – NIH FOCUSED January 17, 2018 - January 18, 2018
    Long Island High Technology Incubator (LIHTI), Stony Brook NY

    January 17, 2018 - January 18, 2018 8:30 am - 12:00 pm

    More Information Register Now

Events Archives